Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03294109 · ClinicalTrials.gov registry record · Phase 4
Evaluation of Abdominal Wall Block With Liposomal Bupivacaine for Post-Operative Analgesia in Donor Nephrectomy
A Phase 4 study of Pain, Postoperative and Patient Satisfaction, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- Phase 4
- Development phase
- 146
- Enrollment target
- 1
- Study location
NCT03294109 is a Phase 4 study of Pain, Postoperative and Patient Satisfaction that has completed, run by University of California, Los Angeles. The registered enrollment target is 146 participants, below the 271-participant average among 108 other Pain, Postoperative trials with a reported enrollment target (46% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03294109, a Phase 4 study of Pain, Postoperative and Patient Satisfaction, has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 146 participants
- Enrollment target
- 1
- Study location
Study Summary
A blinded randomized control trial in living kidney donors. The study group will receive a liposomal bupivacaine Trans Quadratus Lumborum (TQL) block after the induction of general anesthesia. The following study variables will be collected postoperatively following arrival in the post-anesthesia care unit. Current and maximum intensity pain scores will be documented by nurses in Electronic Health Record (EHR). Total opiate dose consumed every 24 hours will be collected from the EHR and pain diary after discharge. Patient satisfaction will be evaluated using the Revised American Pain Society Patient Outcome Questionnaire (APS-POQ-R) 24 hours' post-procedure. Incidence of nausea will be extracted from nursing notes.
Conditions Studied
Interventions
- DRUG Abdominal wall block with liposomal bupivicaine
Study Locations (1)
California
- Connie Frank Kidney Transplant Center - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 146 participants |
| Start Date | 2018-01-01 |
| Est. Completion | 2020-06-24 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03294109
The ClinicalTrials.gov registry entry for NCT03294109 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 146 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 271-participant average among 108 other Pain, Postoperative trials with a reported enrollment target (46% lower). The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 8 conditions, with Pain, Postoperative appearing as the primary indexed condition, and to 1 intervention - of which Abdominal wall block with liposomal bupivicaine is the first listed.
NCT03294109 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT03294109 about?
NCT03294109 is a clinical study titled "Evaluation of Abdominal Wall Block With Liposomal Bupivacaine for Post-Operative Analgesia in Donor Nephrectomy". A blinded randomized control trial in living kidney donors. The study group will receive a liposomal bupivacaine Trans Quadratus Lumborum (TQL) block after the induction of general anesthesia. The following study variables will be collected postoperatively following arrival in the post-anesthesia ca...
What is the current status of trial NCT03294109?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 146 participants. The study started on 2018-01-01. Estimated completion is 2020-06-24.
What conditions does trial NCT03294109 study?
This clinical trial studies the following conditions: Pain, Postoperative, Patient Satisfaction, Physiological Effects of Drugs, Analgesics, Opioid, Peripheral Nervous System Agents.
What interventions are being tested in trial NCT03294109?
The interventions under investigation include: Abdominal wall block with liposomal bupivicaine (DRUG).
Who is sponsoring clinical trial NCT03294109?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03294109 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pain, Postoperative
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Management of Postoperative Discomfort in Young Children Following Dental Rehabilitation Under General Anesthesia
RECRUITING · Phase 4
-
Opioids Versus Non-Opioids Postoperative After Knee Arthroscopic Surgery
RECRUITING · Phase 4
-
The Effect of Zolpidem on Outcomes Following Lumbar Spine Fusion
RECRUITING · Phase 4
-
Comparing Analgesic Regimen Effectiveness and Safety for Surgery (CARES) Trial
RECRUITING · Phase 4
-
IPACK on Early Pain Scores After ACL Reconstruction
RECRUITING · Phase 4
-
Liposomal Bupivacaine Versus Lidocaine for Skin Graft Donor Site Pain
RECRUITING · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.